Telomir Pharma surges on early data for epigenetic drug

Shares of drug developer Telomir Pharmaceuticals TELO.O surges 59% to $2.35 premarket

Late Wednesday, co said lead experimental drug, Telomir-1, shows potential as first-in-class epigenetic therapy for cancer, age-related diseases

Co says it effectively blocks UTX, a gene regulation enzyme, and can help reset abnormal DNA methylation patterns

Also shows selective activity against other epigenetic targets linked to tumor growth, inflammation

Epigenetic therapies aim to change how genes are switched on or off without altering the DNA itself

As of last close, stock down 64% YTD